353 related articles for article (PubMed ID: 38672496)
21. Leptin and Notch Signaling Cooperate in Sustaining Glioblastoma Multiforme Progression.
Panza S; Russo U; Giordano F; Leggio A; Barone I; Bonofiglio D; Gelsomino L; Malivindi R; Conforti FL; Naimo GD; Giordano C; Catalano S; Andò S
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32526957
[TBL] [Abstract][Full Text] [Related]
22. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival.
Huber RM; Rajski M; Sivasankaran B; Moncayo G; Hemmings BA; Merlo A
PLoS One; 2013; 8(2):e57793. PubMed ID: 23451269
[TBL] [Abstract][Full Text] [Related]
23. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.
Sun T; Patil R; Galstyan A; Klymyshyn D; Ding H; Chesnokova A; Cavenee WK; Furnari FB; Ljubimov VA; Shatalova ES; Wagner S; Li D; Mamelak AN; Bannykh SI; Patil CG; Rudnick JD; Hu J; Grodzinski ZB; Rekechenetskiy A; Falahatian V; Lyubimov AV; Chen YL; Leoh LS; Daniels-Wells TR; Penichet ML; Holler E; Ljubimov AV; Black KL; Ljubimova JY
Cancer Res; 2019 Mar; 79(6):1239-1251. PubMed ID: 30659021
[TBL] [Abstract][Full Text] [Related]
24. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.
Floyd DH; Kefas B; Seleverstov O; Mykhaylyk O; Dominguez C; Comeau L; Plank C; Purow B
Neuro Oncol; 2012 Oct; 14(10):1215-26. PubMed ID: 22962413
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
26. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs involved in the EGFR pathway in glioblastoma.
Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
[TBL] [Abstract][Full Text] [Related]
29. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
Nana AW; Yang PM; Lin HY
Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
[TBL] [Abstract][Full Text] [Related]
30. A role for the transcription factor HEY1 in glioblastoma.
Hulleman E; Quarto M; Vernell R; Masserdotti G; Colli E; Kros JM; Levi D; Gaetani P; Tunici P; Finocchiaro G; Baena RR; Capra M; Helin K
J Cell Mol Med; 2009 Jan; 13(1):136-46. PubMed ID: 18363832
[TBL] [Abstract][Full Text] [Related]
31. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
[TBL] [Abstract][Full Text] [Related]
32. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
33. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Drakulic D; Schwirtlich M; Petrovic I; Mojsin M; Milivojevic M; Kovacevic-Grujicic N; Stevanovic M
Cells; 2022 Aug; 11(16):. PubMed ID: 36010607
[TBL] [Abstract][Full Text] [Related]
34. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
35. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
36. AKT/GSK3β Signaling in Glioblastoma.
Majewska E; Szeliga M
Neurochem Res; 2017 Mar; 42(3):918-924. PubMed ID: 27568206
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.
Garner JM; Fan M; Yang CH; Du Z; Sims M; Davidoff AM; Pfeffer LM
J Biol Chem; 2013 Sep; 288(36):26167-26176. PubMed ID: 23902772
[TBL] [Abstract][Full Text] [Related]
38. Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.
Nandhu MS; Behera P; Bhaskaran V; Longo SL; Barrera-Arenas LM; Sengupta S; Rodriguez-Gil DJ; Chiocca EA; Viapiano MS
Clin Cancer Res; 2018 Feb; 24(4):821-833. PubMed ID: 29146721
[No Abstract] [Full Text] [Related]
39. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
40. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
